trial · primary record
Recombinant zoster vaccine(CHO cell)(low adjuvant)
Herpes Zoster
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 960 |
| Primary completion | 2028-09-16 |
| Primary endpoint | The incidence of solicited local and systemic adverse events (AEs) within 0-14 days after each vaccine dose. |
| Registry ID | NCT06851832 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:39.076Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06851832
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.